Real-world experience with cabazitaxel in patients with metastatic castration-resistant prostate cancer: a final, pooled analysis of the compassionate use programme and early access programme

BACKGROUND: Cabazitaxel is a second-generation taxane approved for use in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel. Early access programmes were established to allow eligible patients with mCRPC access to cabazitaxel before regulatory ap...

Descripción completa

Detalles Bibliográficos
Autores principales: Malik, Zafar, Heidenreich, Axel, Bracarda, Sergio, Ardavanis, Alexandros, Parente, Philip, Scholz, Hans-Joerg, Ozatilgan, Ayse, Ecstein-Fraisse, Evelyne, Hitier, Simon, Di Lorenzo, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6609246/
https://www.ncbi.nlm.nih.gov/pubmed/31289614
http://dx.doi.org/10.18632/oncotarget.27031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6609246/
https://www.ncbi.nlm.nih.gov/pubmed/31289614
http://dx.doi.org/10.18632/oncotarget.27031

Ejemplares similares